Pharmacokinetic and pharmacodynamic modeling of a humanized anti-IL-13 antibody in naive and ascaris-challenged cynomolgus monkeys

Pharmaceutical Research

Volumn 26, Issue 2, 2009, Pages 306-315

  Vugmeyster, Yulia ^a   Tian, Xianbin ^a   Szklut, Pamela ^a   Kasaian, Marion ^a   Xu, Xin ^a  

^a PFIZER INC   (United States)

Author keywords

Asthma; IL 13; Monoclonal antibody; Pharmacodynamics; Pharmacokinetics

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCARIASIS; ASCARIS SUUM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; MACACA; MALE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SIMULATION; SINGLE DRUG DOSE;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASCARIS; ASTHMA; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-13; LIGANDS; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL;

EID: 58549085568     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9739-4     Document Type: Article

References (34)

1. J. H. Anolik M. Aringer 2005 New treatments for SLE: cell-depleting and anti-cytokine therapies Best Pract. Res. Clin. Rheumatol. 19 5 859 878
2. A. N. Economides L. R. Carpenter J. S. Rudge V. Wong E. M. Koehler-Stec C. Hartnett 2003 Cytokine traps: multi-component, high-affinity blockers of cytokine action Nat. Med. 9 1 47 52
3. E. Toussirot D. Wendling 2007 The use of TNF-alpha blocking agents in rheumatoid arthritis: an update Expert Opin. Pharmacother. 8 13 2089 2107
4. M. Ichinose P. J. Barnes 2004 Cytokine-directed therapy in asthma Curr. Drug Targets Inflamm. Allergy 3 3 263 269
5. K. Margolin M. S. Gordon E. Holmgren J. Gaudreault W. Novotny G. Fyfe 2001 Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data J. Clin. Oncol. 19 3 851 856
6. H. Ito M. Takazoe Y. Fukuda T. Hibi K. Kusugami A. Andoh 2004 A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease Gastroenterology 126 4 989 996
7. P. Charles M. J. Elliott D. Davis A. Potter J. R. Kalden C. Antoni 1999 Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis J. Immunol. 163 3 1521 1528
8. A. L. Andrews J. W. Holloway S. M. Puddicombe S. T. Holgate D. E. Davies 2002 Kinetic analysis of the interleukin-13 receptor complex J. Biol. Chem. 277 48 46073 46078
9. D. B. Corry F. Kheradmand 2002 Biology and therapeutic potential of the interleukin-4/interleukin-13 signaling pathway in asthma Am. J. Respir. Med. 1 3 185 193
10. M. Wills-Karp 2004 Interleukin-13 in asthma pathogenesis Curr. Allergy Asthma Rep. 4 2 123 131
11. C. Taube C. Duez Z. H. Cui K. Takeda Y. H. Rha J. W. Park 2002 The role of IL-13 in established allergic airway disease J. Immunol. 169 11 6482 6489
12. J. Padilla E. Daley A. Chow K. Robinson K. Parthasarathi A. N. McKenzie 2005 IL-13 regulates the immune response to inhaled antigens J. Immunol. 174 12 8097 8105
13. G. Grunig M. Warnock A. E. Wakil R. Venkayya F. Brombacher D. M. Rennick 1998 Requirement for IL-13 independently of IL-4 in experimental asthma Science 282 5397 2261 2263
14. D. Vercelli 2002 Genetics of IL-13 and functional relevance of IL-13 variants Curr. Opin. Allergy Clin. Immunol. 2 5 389 393
15. R. K. Kumar C. Herbert D. C. Webb L. Li P. S. Foster 2004 Effects of anticytokine therapy in a mouse model of chronic asthma Am. J. Respir. Crit. Care Med. 170 10 1043 1048
16. G. Yang L. Li A. Volk E. Emmell T. Petley J. Giles-Komar 2005 Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice J. Pharmacol. Exp. Ther. 313 1 8 15
17. M. Wills-Karp J. Luyimbazi X. Xu B. Schofield T. Y. Neben C. L. Karp 1998 Interleukin-13: central mediator of allergic asthma Science 282 5397 2258 2261
18. A. Bree F. J. Schlerman M. Wadanoli L. Tchistiakova K. Marquette X. Y. Tan 2007 IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys J. Allergy Clin. Immunol. 119 5 1251 1257
19. M. T. Kasaian X. Y. Tan M. Jin L. Fitz K. Marquette N. Wood 2008 IL-13 Neutralization by two distinct receptor blocking mechanisms reduces IgE responses and lung inflammation in cynomolgus monkeys J. Pharmacol. Exp. Ther. 325 3 88
20. Y. Vugmeyster P. Szklut L. Tchistiakova W. Abraham M. Kasaian X. Xu 2008 Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms Int. Immunopharmacol. 8 3 477 483
21. L. J. Benincosa F. S. Chow L. P. Tobia D. C. Kwok C. B. Davis W. J. Jusko 2000 Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys J. Pharmacol. Exp. Ther. 292 2 810 816
22. D. E. Mager W. J. Jusko 2001 General pharmacokinetic model for drugs exhibiting target-mediated drug disposition J. Pharmacokinet. Pharmacodyn. 28 6 507 532
23. C. M. Ng E. Stefanich B. S. Anand P. J. Fielder L. Vaickus 2006 Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers Pharm. Res. 23 1 95 103
24. F. S. Chow L. J. Benincosa S. B. Sheth D. Wilson C. B. Davis E. A. Minthorn 2002 Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans Clin. Pharmacol. Ther. 71 4 235 245
25. N. Hayashi Y. Tsukamoto W. M. Sallas P. J. Lowe 2007 A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab Br. J. Clin. Pharmacol. 63 5 548 561
26. K. M. Muller K. M. Arndt A. Pluckthun 1998 Model and simulation of multivalent binding to fixed ligands Anal. Biochem. 261 2 149 158
27. W. L. Tseng H. T. Chang S. M. Hsu R. J. Chen S. Lin 2002 Immunoaffinity capillary electrophoresis: determination of binding constant and stoichiometry for antibody-antigen interaction Electrophoresis 23 6 836 846
28. M. Danhof J. de Jongh E. C. De Lange O. Della Pasqua B. A. Ploeger R. A. Voskuyl 2007 Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis Annu. Rev. Pharmacol. Toxicol. 47 357 400
29. C. W. Adams D. E. Allison K. Flagella L. Presta J. Clarke N. Dybdal 2006 Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab Cancer Immunol. Immunother. 55 6 717 727
30. Y. S. Lin C. Nguyen J. L. Mendoza E. Escandon D. Fei Y. G. Meng 1999 Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor J. Pharmacol. Exp. Ther. 288 1 371 378
31. P. Zia-Amirhosseini E. Minthorn L. J. Benincosa T. K. Hart C. S. Hottenstein L. A. Tobia 1999 Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys J. Pharmacol. Exp. Ther. 291 3 1060 1067
32. P. Fiumara F. Cabanillas A. Younes 2001 Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers Blood 98 9 2877 2878
33. S. M. Wang H. Y. Lei M. C. Huang L. Y. Su H. C. Lin C. K. Yu 2006 Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis J. Clin. Virol. 37 1 47 52
34. J. Gabrielsson, and D. Weiner. Pharmacokinetic and pharmacodynamic data analysis: concept and applications. Swedish Pharmaceutical, Stockholm, 2000.